Skip to main content

Table 3 The effect of infliximab or placebo on glucose metabolism (mean ± SEM)

From: Chronic TNF-α Neutralization Does Not Improve Insulin Resistance or Endothelial Function in “Healthy” Men with Metabolic Syndrome

 

Infliximab

Placebo

 

Day 0

Day 70

Δ day 70–day 0

P a

Day 0

Day 70

Δ day 70–day 0

P a

Fasting glucose (mmol/L)

5.7 ± 0.4

5.4 ± 0.3

−0.1 ± 0.1

nsb

5.4 ± 0.2

5.4 ± 0.2

−0 ± 0.1

ns

Fasting insulin (µU/L)

15.9 ± 3.5

15.9 ± 4.2

−0.9 ± 4

ns

15.2 ± 2.7

13.9 ± 3.3

0.4 ± 1.6

ns

HOMA index

4.2 ± 1.2

3.8 ± 1.0

−0.2 ± 0.9

ns

3.7 ± 0.8

3.4 ± 0.8

0.1 ± 0.4

ns

Insulin sensitivity index (10−4 min−1(µU/mL)−1)

2.2 ± 0.4

1.8 ± 0.4

−0.4 ± 0.1

0.049

1.8 ± 0.5

1.8 ± 0.5

0.1 ± 0.2

ns

  1. aP is for the changes between d 70 to d 0.
  2. bns: not significant.